Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Packerfan666on Jul 27, 2018 1:08pm

66 Views

Post# 28378004

RE:RE:Phase 2B & Herring Creek Pharma

Agreed . Everyone should look and think long and hard. All drug development companies are in deep debt and dilute. They keep trying to make you avoid that fact. What lack of transparency ? Why doesn’t any call the company and ask? I have talked to them 5-6 times and they have answered every question and concern I have had. Just find it funny lakinjuice says haven’t done eat and dog tests but go to their website and read corporate presentation . Clearly say a animal testing may reflect results in human trials. So he talks about them not spewing correct facts when he doesn’t.

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading